Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 107Gliosarcoma 48Glioma 41Brain Neoplasms 38Astrocytoma 38Central Nervous System Neoplasms 30Oligodendroglioma 27Medulloblastoma 15Melanoma 14Neuroblastoma 13Ependymoma 11Neoplasms 10Familial ependymoma 8Choroid Plexus Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 6Sarcoma 6Optic Nerve Glioma 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Sarcoma, Ewing 5Recurrence 5Rhabdoid Tumor 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Lymphoma 4Glioma, Subependymal 4Spinal Cord Neoplasms 3Rhabdomyosarcoma 3Pinealoma 3

Interventions

veliparib 1cixutumumab 1Temozolomide 1Salts 1Omeprazole 1Octreotide 1Lansoprazole 1Everolimus 1Esomeprazole 1Dexlansoprazole 1Clopidogrel 1Capecitabine 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Zollinger-Ellison Syndrome × Temozolomide × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡